The Challenge
Traditional cancer detection and monitoring often rely on invasive tissue biopsies or imaging studies that can be uncomfortable, risky, costly, and may not capture the full heterogeneity of a tumor. Additionally, these methods are typically employed only after symptoms appear or as scheduled follow-ups, potentially missing critical windows for early intervention.
Liquid biopsies—which detect cancer biomarkers in blood or other body fluids—offer a promising alternative, but face significant challenges: extremely low concentrations of cancer-derived materials in the blood, complex signal-to-noise issues, variability in sample processing, and the need for highly sensitive and specific analytical methods that can reliably distinguish cancer signals from normal biological variation.
Our Approach
We aim to apply advanced artificial intelligence to overcome the challenges of liquid biopsy analysis. Our multifaceted approach includes:
- Developing deep learning algorithms for the detection and characterization of ultra-low frequency cancer signals in blood
- Creating multi-modal AI systems that integrate various liquid biopsy components (ctDNA, CTCs, exosomes, proteins) for improved sensitivity and specificity
- Building longitudinal monitoring tools that can detect subtle changes in biomarker profiles over time, potentially indicating disease progression or treatment response
- Designing AI models that can correlate liquid biopsy findings with clinical outcomes to enable more precise prognostication and treatment planning
- Developing specialized approaches for detecting minimal residual disease after treatment to guide adjuvant therapy decisions
Early Detection
AI-powered analysis of circulating biomarkers to detect cancer at the earliest possible stages, potentially before symptoms or imaging findings appear.
Treatment Monitoring
Tracking dynamic changes in liquid biopsy markers during therapy to rapidly assess response, detect resistance emergence, and guide treatment adjustments.
Minimal Residual Disease
Ultra-sensitive detection of remaining cancer cells after primary treatment to inform decisions about adjuvant therapy and identify patients at risk of recurrence.
Tumor Heterogeneity Analysis
Characterizing diverse cancer cell populations and their evolution over time through non-invasive liquid biopsy sampling.
Potential Research Projects
Multi-Analyte Liquid Biopsy Integration
We could develop AI systems that integrate data from multiple circulating biomarkers—including cell-free DNA, circulating tumor cells, extracellular vesicles, proteins, and metabolites—to create a comprehensive liquid biopsy profile. This integrated approach could potentially overcome the limitations of any single biomarker type, improving sensitivity and specificity for early detection and characterization of various cancer types.
Longitudinal Monitoring and Treatment Response
This project would focus on developing AI algorithms that track subtle changes in liquid biopsy profiles over time. By analyzing serial samples, these models could potentially detect early signs of treatment resistance, disease progression, or recurrence well before clinical symptoms or imaging changes become apparent, enabling timely intervention and treatment modification.
Minimal Residual Disease Detection
We aim to create ultra-sensitive AI-powered detection systems for minimal residual disease (MRD) after primary cancer treatment. By identifying patients with residual circulating cancer markers, these tools could help identify who might benefit from additional therapy, potentially preventing recurrence while avoiding unnecessary treatment for those who are truly disease-free.
Cancer Interception and Screening
This ambitious project would develop AI models for cancer screening in high-risk populations or even the general population. By creating highly specific algorithms that can distinguish cancer signals from normal biological variation, we could potentially enable effective screening programs that detect cancer at pre-symptomatic stages when treatment is most likely to be curative.
Technical Innovations
Our liquid biopsy research would leverage several cutting-edge technical approaches:
- Deep learning for fragment analysis: Novel architectures to detect subtle patterns in fragmentation profiles of cell-free DNA
- Multimodal learning: Techniques to integrate multiple biomarker types into unified predictive models
- Anomaly detection: Advanced methods to distinguish cancer-specific signals from normal biological variation
- Transformer models: For analyzing sequential data and capturing long-range dependencies in longitudinal samples
- Methylation pattern analysis: Specialized networks for detecting cancer-specific DNA methylation signatures
- Federated learning: Privacy-preserving approaches to leverage data from multiple institutions without compromising patient privacy
Biomarker Types
Our research would address multiple circulating biomarker types:
Circulating Tumor DNA
Developing AI for the detection and analysis of DNA fragments released by tumor cells, including mutations, copy number alterations, and epigenetic changes.
Circulating Tumor Cells
Creating computer vision approaches for characterizing rare intact cancer cells in circulation, including morphological and functional properties.
Extracellular Vesicles
Building AI systems to analyze tumor-derived exosomes and their cargo, including proteins, RNA, and metabolites that reflect the state of the parent cancer.
Cancer Applications
Liquid biopsy analysis could be particularly impactful for specific cancer types:
Lung Cancer
Early detection in high-risk populations, monitoring for resistance mutations during targeted therapy, and detection of minimal residual disease after surgery.
Colorectal Cancer
Screening approaches based on circulating DNA methylation patterns, monitoring for recurrence, and characterizing molecular heterogeneity.
Breast Cancer
Tracking treatment response in metastatic disease, detecting minimal residual disease after primary therapy, and monitoring for resistance emergence.
Pancreatic Cancer
Early detection strategies for this difficult-to-diagnose cancer, potentially enabling intervention at stages when surgical cure is still possible.
Future Directions
As our research progresses, we plan to explore several exciting directions:
- Developing AI-powered point-of-care devices for rapid liquid biopsy analysis in clinical settings
- Creating cancer origin prediction models that can identify the tissue of origin for early-stage cancers detected through liquid biopsy
- Building integrated predictive models that combine liquid biopsy data with imaging, clinical, and pathological information
- Exploring the use of liquid biopsies for evaluating immune responses and predicting immunotherapy effectiveness
- Developing population-scale screening approaches that are cost-effective and clinically actionable
Collaborations and Partnerships
We would be interested in exploring partnerships with:
Diagnostic Companies
To translate our AI-powered liquid biopsy technologies into clinically validated diagnostic tools
Clinical Trial Networks
To incorporate liquid biopsy analyses into clinical trials for biomarker discovery and validation
Cancer Research Institutions
To access biobanks and longitudinal patient samples for model training and validation
Research Background
This research area contributes to the growing body of knowledge in AI-powered cancer research. We're currently developing foundational work in this space.
Related Research Areas
Stay Updated
Subscribe to receive updates on our latest research findings and breakthroughs.